Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6346 to 6360 of 7711 results

  1. Daylight for treating generalised anxiety disorder in adults (MIB309)

    August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.

  2. SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

    Discontinued [GID-MT516]

  3. Abicipar pegol for treating wet age-related macular degeneration ID1533

    In development [GID-TA10511] Expected publication date: TBC

  4. Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]

    Discontinued [GID-TA10394]

  5. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued [GID-TA11119]

  6. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued [GID-TA10197]

  7. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued [GID-TA10149]

  8. Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

    Discontinued [GID-TA10546]

  9. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued [GID-TA10355]

  10. Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

    Discontinued [GID-TA10081]

  11. Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

    Discontinued [GID-TA10087]

  12. Seven day working

    Discontinued [GID-QS10108]

  13. Mental health community settings

    Discontinued [GID-SGWAVE0702]

  14. OraQuick® HCV Rapid Antibody Test (discontinued)

    Discontinued [GID-MT117]